SABCS 2022: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 + Q & A
HTML-код
- Опубликовано: 16 окт 2024
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
Recorded @ SABCS 2022, December 7/More about SABCS Reports @ oncoletter.ch